<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014621</url>
  </required_header>
  <id_info>
    <org_study_id>CLP0050615</org_study_id>
    <nct_id>NCT04014621</nct_id>
  </id_info>
  <brief_title>Augmenting Cerebral Blood Flow to Preserve the Penumbra Trial</brief_title>
  <acronym>ImpACT-P</acronym>
  <official_title>A Multicenter, Randomized, Double Blind, Sham Controlled Trial to Assess the Efficacy of the Ischemic Stroke System (ISS) in Preventing Progressive Reduction of Salvageable Brain Tissue Volume in Subjects With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BrainsGate</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BrainsGate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate that SPG (Sphenopalatine Ganglion)&#xD;
      stimulation started within 6 hours from stroke onset slows the expansion of the infarct core&#xD;
      volume in acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to identify Acute Ischemic Stroke patients who have a potentially&#xD;
      salvageable penumbra and to test if 6 hours of SPG (Sphenopalatine Ganglion) stimulation may&#xD;
      &quot;freeze&quot; the volume of the penumbra and reduce the extent of tissue death.&#xD;
&#xD;
      Following a minimally-invasive implantation of the ISS injectable implant, patients will be&#xD;
      randomized to either the Treated or Control arm in a 1:1 ratio. Randomization will be dynamic&#xD;
      according to the patient's baseline covariates of core volume, total volume, Hypoperfusion&#xD;
      Intensity Ratio (HIR), time to baseline imaging, age, NIHSS. Patients in the Treated arm will&#xD;
      be treated with active SPG stimulation while patients in the Control arm will undergo sham&#xD;
      treatment. After treatment/sham treatment, patients in both groups will undergo a follow up&#xD;
      brain non-contrast CT, CT perfusion and CT angiography imaging, 6:45hrs±15min after baseline&#xD;
      CTP initiation.&#xD;
&#xD;
      In the case the patient is cooperative, hand strength (pinch and grasp) evaluations should be&#xD;
      assessed before and during the 1st treatment/ sham SPG stimulation session.&#xD;
&#xD;
      Following the assessment of the penumbra (after 6 hours) patients will be treated or sham&#xD;
      treated for 5 additional consecutive sessions (4 hours each), the first starting within 18-24&#xD;
      hours from stroke onset and the others 18-26 hours from previous treatment initiation and&#xD;
      will be followed for 90 days to assess their clinical outcome. In one session (preferably at&#xD;
      day 2) Common Carotid Doppler examination is performed to evaluate blood flow dynamics before&#xD;
      and during the treatment/sham session.&#xD;
&#xD;
      After the last treatment session, the implant is removed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 20, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of core expansion</measure>
    <time_frame>Day 1</time_frame>
    <description>The primary outcome measure is the volume of core expansion (in milliliters) in 6:45h±15 min. Core expansion is the difference of two volumes: Core volume (CBF&lt;38%) in follow up CTP (at 6:45h±15 min) and Core volume (CBF&lt;38%) in baseline CTP.&#xD;
The difference in the mean core expansion between the Treated and Control groups will be assessed as a continuous variable with adjustment for baseline covariates (Core volume, Total volume, HIR, Time to baseline imaging).&#xD;
The two-sided significance level is 0.05.&#xD;
Handling of missing data in the primary analysis:&#xD;
Patients who die before the 6:45h±15 min follow-up imaging will be assigned a final core volume that equal the baseline total volume.&#xD;
Patients with non-interpretable follow-up imaging will be excluded from the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in infarct volume between baseline CTP core volume and follow up NCCT infarct volume.</measure>
    <time_frame>Day 1</time_frame>
    <description>Difference in infarct volume (in milliliters) between baseline CTP core volume (CBF&lt;38%) and follow up 6:45h±15 min NCCT infarct volume, adjusted using stratification parameters (Core volume, Total volume, HIR, Time to baseline imaging).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in infarct volume between baseline CTP core volume and Day-5 NCCT infarct volume</measure>
    <time_frame>Day 5</time_frame>
    <description>Difference in infarct volume (in milliliters) between baseline CTP core volume (CBF&lt;38%) and Day-5 NCCT infarct volume, adjusted using stratification parameters (Core volume, Total volume, HIR, Time to baseline imaging).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 months mRS</measure>
    <time_frame>Day 90±7</time_frame>
    <description>mRS at 90-day:&#xD;
Utility weighted mRS&#xD;
mRS Dichotomy 0-2&#xD;
mRS Dichotomy 0-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increased blood flow in Common Carotid Doppler</measure>
    <time_frame>Day 2-6</time_frame>
    <description>Increased blood flow in Common Carotid Doppler (if available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in hand motor performance</measure>
    <time_frame>Day 1</time_frame>
    <description>Improvement in hand motor performance (if available) using a hand dynamometer (Baseline Hydraulic Hand Dynamometers, Fabrication Enterprises Inc, White Plains NY, USA).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Data Between the Treatment and Control Arms - Serious Adverse Events</measure>
    <time_frame>Day 90±7</time_frame>
    <description>Incidence of Serious Adverse Events</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Data Between the Treatment and Control Arms - Mortality</measure>
    <time_frame>Day 90±7</time_frame>
    <description>Incidence of Mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Data Between the Treatment and Control Arms - Symptomatic Intracranial hemorrhage (sICH) SAEs</measure>
    <time_frame>Day 5</time_frame>
    <description>Incidence of symptomatic intracranial hemorrhage (sICH) SAEs</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Data Between the Treatment and Control Arms - Pain</measure>
    <time_frame>Day 1 to 5</time_frame>
    <description>Incidence of Pain adverse events during stimulation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Treated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated arm patients will be implanted and treated with one session of SPG stimulation for 6 hours and 5 additional consecutive sessions (4 hours each) of SPG stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Control arm patients will be implanted and receive 6 hours of sham stimulation and 5 additional consecutive sessions (4 hours each) of sham stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPG stimulation</intervention_name>
    <description>The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signs &amp; symptoms consistent with the diagnosis of large vessel occlusion in the&#xD;
             anterior circulation&#xD;
&#xD;
          2. Age 18-90 years&#xD;
&#xD;
          3. Baseline NIHSS ≥ 10&#xD;
&#xD;
          4. Ability to initiate treatment within 6 hours from stroke onset. Stroke onset is&#xD;
             defined as the time the patient was last seen well.&#xD;
&#xD;
          5. Large vessel total occlusion by CTA&#xD;
&#xD;
          6. Penumbra ≥ 50ml (Difference between Tmax6 volume and the ischemic core volume (CBF&lt;38%&#xD;
             volume)&#xD;
&#xD;
          7. Mismatch (Tmax6 volume/ischemic core volume (CBF&lt;38% volume) ≥1.5&#xD;
&#xD;
          8. Core and HIR (Tmax10 / Tmax6) volumes: 1. HIR ≥ 0.5 or 2. 0.35 ≤ HIR &lt; 0.5 and &quot;core&#xD;
             volume/time from onset to imaging&quot; ≥ 7mililiter/hour&#xD;
&#xD;
          9. Signed informed consent from patient him/herself or legally authorized representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to undergo a contrast brain perfusion scan, including an allergy to contrast&#xD;
             media&#xD;
&#xD;
          2. Opportunity for reperfusion therapy (IV thrombolysis or endovascular treatment)&#xD;
&#xD;
          3. Neuro-imaging evidence of any intracranial hemorrhage or hemorrhagic transformation of&#xD;
             brain infarct or other significant abnormality (e.g. tumor, abscess, suspect for&#xD;
             subarachnoid hemorrhage, arteriovenous malformation, cerebral aneurysm).&#xD;
&#xD;
          4. Significant mass effect with midline shift.&#xD;
&#xD;
          5. Infarct core volume &gt;150 milliliter&#xD;
&#xD;
          6. Old non-lacunar infarct in the anterior circulation on the ipsilateral hemisphere.&#xD;
&#xD;
          7. Previous stroke in the last 6 months or previous stroke with existing sequelae or with&#xD;
             mRS &gt; 0 for any reason&#xD;
&#xD;
          8. Pre-existing Modified Rankin Score &gt;1, even if not stroke-related.&#xD;
&#xD;
          9. Acute symptomatic arterial occlusions in more than one vascular territory confirmed on&#xD;
             CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).&#xD;
&#xD;
         10. Seizures at stroke onset&#xD;
&#xD;
         11. Baseline blood glucose of &lt;50mg/dL (2.78 mmol) or &gt;400mg/dL (22.20 mmol)&#xD;
&#xD;
         12. Severe, sustained hypertension (Systolic BP &gt;185 mmHg or Diastolic BP &gt;110 mmHg)&#xD;
&#xD;
         13. Current participation in another investigational drug or device study&#xD;
&#xD;
         14. Presumed septic embolus; suspicion of bacterial endocarditis&#xD;
&#xD;
         15. Clinical signs and symptoms or evidence for a relevant lesion by neuro-imaging of an&#xD;
             acute ischemic stroke in the posterior circulation (Vertebral, Basilar and/or&#xD;
             Posterior Cerebral Artery territories), including but not limited to brain-stem&#xD;
             findings and/or cerebellar findings and/or isolated homonymous hemianopia or cortical&#xD;
             blindness.&#xD;
&#xD;
         16. Patients with bleeding propensity and/or one of the following: INR &gt; 1.8, prolonged&#xD;
             activated partial thromboplastin time (aPTT) ≥ 45 sec., platelets count &lt; 75×10^9/L.&#xD;
&#xD;
         17. Serious systemic infection.&#xD;
&#xD;
         18. Women known to be pregnant or having a positive or indeterminate pregnancy test.&#xD;
&#xD;
         19. Patients with other implanted neural stimulator/ electronic devices (pacemakers).&#xD;
&#xD;
         20. History of SPG ablation ipsilateral to the stroke side.&#xD;
&#xD;
         21. Any condition in the oral cavity that prevents implantation of the INS.&#xD;
&#xD;
         22. Known sensitivity to any medications to be used during study.&#xD;
&#xD;
         23. Subjects who have a clinically significant or unstable medical or surgical condition&#xD;
             that may preclude safe and complete study participation. Conditions may include:&#xD;
             cardiovascular, vascular, pulmonary, hepatic, renal or neurological (other than acute&#xD;
             ischemic stroke), or neoplastic diseases, as determined by medical history, physical&#xD;
             examination, laboratory tests, or ECG.&#xD;
&#xD;
         24. Subjects who, in the judgment of the investigator, are likely to be non-compliant or&#xD;
             uncooperative during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoram Slolberg, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>BrainsGate</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Segev</last_name>
    <phone>+972 4 637 7774</phone>
    <phone_ext>115</phone_ext>
    <email>michaels@brainsgate.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noam Levy</last_name>
    <phone>+972 4 637 7774</phone>
    <phone_ext>103</phone_ext>
    <email>noaml@brainsgate.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academian Z.Tskhakaia West Georgia National Center of Interventional Medicine</name>
      <address>
        <city>Kutaisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Janelidze, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rustavi Central Hospital</name>
      <address>
        <city>Rustavi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nino Kharaishvili, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>K. Eristavi National center of clinical and experimental surgery's hospital &quot;New Life&quot;</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natia Zarkua, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LTD High Technology Medical Center University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgi Ingorokva, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>randomized clinical trial</keyword>
  <keyword>anterior circulation</keyword>
  <keyword>penumbra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

